AstraZeneca vaccine changes name to Vaxevri …

British-Swedish pharmaceutical company AstraZeneca and UK University of Oxford’s coronavirus vaccine changed name to Vaxzevria. The amendment was approved by the European Medicines Agency (EMA) on March 25. Several countries had suspended their vaccination campaigns after the detection of cases of thrombosis, although they later resumed them when the same control agency of the European Union judged it to be “safe and effective” and that there was no proven relationship between its application and these conditions.

Health authorities explained that the name change was required by the company and there was no change in the formulation of the drug. However, from the EMA, they pointed out that immunization officials in different countries are aware of the change, because product information, labeling and packaging may be different.

In recent days it has been confirmed that AstraZeneca and Oxford University vaccine is 76% effective against symptomatic forms of coronavirus, based on updated data from a clinical trial conducted in the United States, Peru and Chile. The vaccine, in addition, it is 100% effective in preventing severe cases of covid-19.

The results of “the primary analysis of phase III (vaccine) trials in the United States confirmed that (their) efficacy was in line” with previously announced data, AstraZeneca said in its memo.

Over the past few weeks, several European Union countries have temporarily suspended their vaccination campaigns after detection of cases of thrombosis. Inoculation resumed after EMA assured Oxford-AstraZeneca vaccine “safe and effective”.